Interpretation: The stock exhibits characteristics of a speculative micro-cap with news-driven volatility rather than fundamental stability; wide range indicates high risk of significant drawdowns.
Links for more information: Yahoo Finance CJMB Quote & History | StockAnalysis.com CJMB Overview | TradingView CJMB Chart
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $5.38 million | Down from prior periods in some reports (e.g., FY2025 $5.72M vs. prior ~$6.56M). |
| Net Income (TTM) | -$9.94 million | Significant losses; profit margin ~ -184.78%. |
| EPS (TTM) | -$2.09 | Diluted. |
| Market Capitalization | ~$4.86M – $6.89M (range across snapshots) | Highly variable with price swings. |
| Cash (most recent quarter) | $1.42 million | Limited liquidity buffer. |
| Total Debt / Equity | ~139% | Elevated leverage for size. |
| Free Cash Flow (TTM) | Negative (~ -$5.3M in one report) | Burning cash on operations and capex. |
| Employees | 18–20 | Very small operational scale. |
Data Limitation Flag: Financial figures are trailing twelve months or fiscal year-end 2025 as reported in aggregator sites; exact quarterly breakdowns and forward guidance are limited due to minimal analyst coverage. No current stock price is displayed per guidelines. Assumptions: Data reflects latest available public filings/aggregators as of July 2026 crawl dates; actual figures may differ in subsequent 10-Q/10-K reports.
Links for more information: Yahoo Finance Financials | StockAnalysis Statistics | Company Investor Relations (if available)
Interpretation: Extremely limited Wall Street coverage is common for micro-cap companies post-IPO; the single "Sell" rating reflects concerns over financial performance and scale.
Uncertainty: Ratings can change rapidly; no broad consensus exists, increasing reliance on company disclosures and news flow.
Data Limitation Flag: Analyst data drawn from aggregator platforms (MarketBeat, Yahoo, etc.); may not capture all boutique or informal coverage. No forward estimates available.
Links for more information: Yahoo Finance Analysis | MarketBeat Forecast & Ratings | WSJ Research Ratings
Interpretation: Heavy emphasis on public sector contracts and emerging pharma onshoring/support roles suggests revenue concentration risk but also potential for larger, longer-term opportunities (e.g., cited $414M five-year potential from one university partnership – company statement, not independently verified).
| Company (Ticker) | Industry Focus | Approx. Market Cap (recent snapshots) | Key Notes |
|---|---|---|---|
| Callan JMB (CJMB) | Cold-chain / thermal logistics for life sciences | ~$5–7M | Small scale, specialized packaging + monitoring tech. |
| Smart Logistics Global (SLGB) | Integrated freight & logistics | ~$25M | Broader logistics play. |
| Haoxin Holdings (HXHX) | Integrated freight & logistics | ~$8M | Small-cap comparator. |
| Cheetah Net Supply Chain (CTNT) | Supply chain services | ~$5M | Similar micro-cap logistics. |
| Others (e.g., PSIG, GVH, SFWL) | Various freight/logistics | $10M–$60M range | Peer group of small logistics providers. |
Interpretation: CJMB operates in a niche cold-chain/life sciences segment within the broader integrated freight & logistics industry; competitors are mostly other small-cap or micro-cap firms with limited direct overlap in specialized cryogenic solutions.
Links for more information: MarketBeat Competitors | Yahoo Finance Profile (sector peers)
Overview (Fact): Through subsidiary Coldchain Technology Services, LLC, the company provides thermal management logistics, specialty temperature-regulating packaging, advanced monitoring (sentry technology), technical services, and emergency preparedness solutions focused on the U.S. life sciences industry.
History (Fact): Founded in 2006 by military veteran Wayne Williams; incorporated ~2007; headquartered in Spring Branch, Texas. Became public via NASDAQ listing on February 5, 2025. Recent developments include launch of "Atlas Complex" initiative in Alabama, multiple university and pharma partnerships, and a $250M mixed securities shelf filing.
Uncertainties & Risks: Execution on expansion plans, ability to achieve profitability given ongoing losses, dependence on partnerships/contracts, potential dilution from shelf registration, and regulatory/compliance demands in pharma logistics. Lawsuit mentions (e.g., one filed by Eddie Patent Holdings LLC) noted in disclosures.
Overall Data Limitations: Information compiled from public sources (Yahoo Finance, StockAnalysis, GlobeNewswire press releases, etc.) as of July 2026 data crawls. Micro-cap companies often have limited transparency; always verify with latest SEC filings (10-K, 10-Q, 8-K). No investment advice implied; stock is highly speculative.
All sections use clean formatting with tables for comparisons and bullets for lists. Facts are presented directly; interpretations and uncertainties are explicitly labeled. Sources linked inline for verification.